118 related articles for article (PubMed ID: 38467878)
1. Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn LB; Khuong-Quang DA; Hansford JR; Landi D; van der Lugt J; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Waanders AJ; Ziegler DS; Witt O; Baxter PA; Kang HJ; Hassall TE; Han JW; Hargrave D; Franson AT; Yalon Oren M; Toledano H; Larouche V; Kline C; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; Chi SN; Oren L; Tan EEK; Mueller S; Cornelio I; McLeod L; Zhao X; Walter A; Da Costa D; Manley P; Blackman SC; Packer RJ; Nysom K
Nat Med; 2024 May; 30(5):1500. PubMed ID: 38467878
[No Abstract] [Full Text] [Related]
2. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn LB; Khuong-Quang DA; Hansford JR; Landi D; van der Lugt J; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Waanders AJ; Ziegler DS; Witt O; Baxter PA; Kang HJ; Hassall TE; Han JW; Hargrave D; Franson AT; Yalon Oren M; Toledano H; Larouche V; Kline C; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; Chi SN; Oren L; Tan EEK; Mueller S; Cornelio I; McLeod L; Zhao X; Walter A; Da Costa D; Manley P; Blackman SC; Packer RJ; Nysom K
Nat Med; 2024 Jan; 30(1):207-217. PubMed ID: 37978284
[TBL] [Abstract][Full Text] [Related]
3. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Rasco DW; Medina T; Corrie P; Pavlick AC; Middleton MR; Lorigan P; Hebert C; Plummer R; Larkin J; Agarwala SS; Daud AI; Qiu J; Bozon V; Kneissl M; Barry E; Olszanski AJ
Cancer Chemother Pharmacol; 2023 Jul; 92(1):15-28. PubMed ID: 37219686
[TBL] [Abstract][Full Text] [Related]
5. Targeted Options for Glioma Looking Good.
Cancer Discov; 2023 Aug; 13(8):1755. PubMed ID: 37276325
[TBL] [Abstract][Full Text] [Related]
6. How will tovorafenib change our treatment of pediatric low-grade glioma?
Yaman I; Bouffet E
Expert Opin Emerg Drugs; 2024 Mar; 29(1):1-3. PubMed ID: 38293894
[No Abstract] [Full Text] [Related]
7. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory
Hargrave DR; Terashima K; Hara J; Kordes UR; Upadhyaya SA; Sahm F; Bouffet E; Packer RJ; Witt O; Sandalic L; Kieloch A; Russo M; Cohen KJ;
J Clin Oncol; 2023 Nov; 41(33):5174-5183. PubMed ID: 37643378
[TBL] [Abstract][Full Text] [Related]
8. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract][Full Text] [Related]
9. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib.
Tkacik E; Li K; Gonzalez-Del Pino G; Ha BH; Vinals J; Park E; Beyett TS; Eck MJ
J Biol Chem; 2023 May; 299(5):104634. PubMed ID: 36963492
[TBL] [Abstract][Full Text] [Related]
10. Tovorafenib effective against low-grade gliomas harbouring BRAF fusions.
Sidaway P
Nat Rev Clin Oncol; 2024 Feb; 21(2):83. PubMed ID: 38082106
[No Abstract] [Full Text] [Related]
11. Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel
Offer K; McGuire MT; Song K; Goldfischer MJ; Davare MA; Corless CL; Beadling C; Neff T; Cox MC; Govinda Raju S; Blackman SC
JCO Precis Oncol; 2023 Jul; 7():e2300065. PubMed ID: 37410972
[No Abstract] [Full Text] [Related]
12. Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX).
Leblond P; Tresch-Bruneel E; Probst A; Néant N; Solas C; Sterin A; Boulanger T; Aerts I; Faure-Conter C; Bertozzi AI; Chastagner P; Entz-Werlé N; De Carli E; Deley ML; Bouche G; André N
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046681
[TBL] [Abstract][Full Text] [Related]
13. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI; Colman H; Rosenthal M; Van Tine BA; Levacic D; Walbert T; Gan HK; Vieito M; Milhem MM; Lipford K; Forsyth S; Guichard SM; Mikhailov Y; Sedkov A; Brevard J; Kelly PF; Mohamed H; Monga V
Neuro Oncol; 2023 Jan; 25(1):146-156. PubMed ID: 35639513
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Dabrafenib in Pediatric Patients with
Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric
Bouffet E; Geoerger B; Moertel C; Whitlock JA; Aerts I; Hargrave D; Osterloh L; Tan E; Choi J; Russo M; Fox E
J Clin Oncol; 2023 Jan; 41(3):664-674. PubMed ID: 36375115
[TBL] [Abstract][Full Text] [Related]
17. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
[TBL] [Abstract][Full Text] [Related]
18. Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.
Trippett T; Toledano H; Campbell Hewson Q; Verschuur A; Langevin AM; Aerts I; Howell L; Gallego S; Rossig C; Smith A; Patel D; Pereira LR; Cheeti S; Musib L; Hutchinson KE; Devlin C; Bernardi R; Geoerger B
Target Oncol; 2022 May; 17(3):283-293. PubMed ID: 35715627
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)
Gaspar N; Campbell-Hewson Q; Gallego Melcon S; Locatelli F; Venkatramani R; Hecker-Nolting S; Gambart M; Bautista F; Thebaud E; Aerts I; Morland B; Rossig C; Canete Nieto A; Longhi A; Lervat C; Entz-Werle N; Strauss SJ; Marec-Berard P; Okpara CE; He C; Dutta L; Casanova M
ESMO Open; 2021 Oct; 6(5):100250. PubMed ID: 34562750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
